Skip to content
Decision-ready map
• Market opportunity: safer, inclusive light therapy
• Key risk: melanin-dependent heating → burns/pigment harm + liability
• Evidence + regulation: disparity signals → stronger validation expectations
• Differentiation: dose-control design + stratified safety evidence
(1) What it is
For founders, thermal injury disparity is a product and deployment risk driven by optics (absorption), physiology (perfusion, hydration), and protocol design (irradiance, fluence, pulse, spot size, coupling). When melanin absorbs a meaningful portion of delivered energy, higher pigmentation can produce higher local heating for the same settings. That can increase burns, discomfort, pigmentary sequelae, and distrust. Translation success requires dose control, safe defaults, and stratified safety evidence.
(2) Who it helps
This brief supports founders building PBM devices, dermatologic laser/IPL platforms, consumer LED products, or standardized protocol services—especially those marketed as “for all skin types” or intended for home/non-specialist use.
(3) What evidence exists
A 2025 retrospective cohort study reports darker skin color associated with increased photosensitivity and substantially higher odds of clinically visible thermal injuries during dual-wavelength low-power laser therapy (https://doi.org/10.1111/phpp.70042). Reviews of laser/light complications in skin of color describe heightened vulnerability to injury and pigmentary changes without parameter adaptation (https://doi.org/10.4103/ijdvl.IJDVL_88_17). IPL complications reviews include burns and pigmentary changes and connect prevention to parameter selection (https://doi.org/10.1002/der2.57). PBM dosimetry discussions emphasize that inconsistent parameter reporting undermines safety and comparability (https://doi.org/10.21037/atm.2016.05.34). FDA’s PBM draft guidance outlines expectations for testing and labeling when pursuing medical device claims (FDA webpage).
(4) Translation barriers
Key barriers include high variability in real-world coupling and cooling, ambiguous skin tone measurement, and marketing pressure to claim universal safety without stratified data. Many products report nominal power but omit spot size, irradiance at tissue, and duty cycle, making “dose” unclear and preventing reproducible safety evaluation. Scaling increases operator variability and misuse risk.
(5) Equity/safety checks
Turn safety parity into engineering deliverables: bounded parameter ranges, conservative defaults, guided titration, required cooling/coupling instructions, and (where feasible) sensing (temperature, contact, distance) with auto-stop. Validate safety across skin tones with pre-specified subgroup endpoints (burns, pain, pigment changes). Publish an “equity dossier” for buyers: stratified adverse-event rates and conditions tested.
(6) Decision questions
• What is the claim category (medical vs aesthetic vs wellness) and does your evidence plan match it?
• Which chromophores are targeted at your wavelengths, and how does melanin absorption affect heat risk?
• How will you measure skin tone/phototype and stratify safety outcomes?
• What post-market plan detects adverse-event disparities after updates or scaling?
(7) Practical next steps
1) Build a validation roadmap: thermal modeling/bench tests → controlled pilot → pragmatic deployment study with subgroup reporting.
2) Adopt a complete parameter schema (wavelength, irradiance, fluence, pulse, spot size, coupling, cooling) and enforce it in logs.
3) Align documentation and labeling with FDA guidance if medical claims are intended.
4) Create UI guardrails and training that prevent “one-setting-fits-all” misuse.
(8) References
https://doi.org/10.1111/phpp.70042
https://doi.org/10.4103/ijdvl.IJDVL_88_17
https://doi.org/10.1002/der2.57
https://doi.org/10.21037/atm.2016.05.34
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/photobiomodulation-pbm-devices-premarket-notification-510k-submissions